We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UG Stock Gains 28% After Q3 Earnings Surge Y/Y on Sales Growth
Read MoreHide Full Article
Shares of United-Guardian, Inc. (UG - Free Report) have risen 28% since reporting results for the third quarter of 2026, outperforming the S&P 500 index’s 1.9% return. Over the past month, the stock has gained 25.2%, contrasting with the S&P 500’s 4.5% decline.
United-Guardian reported third-quarter 2026 net sales of $3.49 million, up 54% from $2.26 million in the year-ago quarter. Net income surged 247% to $930,912 from $268,441 in the year-ago quarter. Earnings per share increased to 20 cents from 6 cents in the prior-year period. The substantial improvement in profitability reflected higher sales across the company’s pharmaceuticals, personal care ingredients and medical lubricants businesses, alongside relatively modest growth in total costs and expenses.
United-Guardian, Inc. Price, Consensus and EPS Surprise
Income from operations increased significantly to $1.11 million from $215,072 in the prior-year quarter, reflecting improved operating efficiency and stronger sales performance.
Cost of sales increased 23.5% year over year to $1.62 million from $1.31 million, substantially below the 54% revenue growth rate. Consequently, gross profit increased to $1.88 million from $953,069 in the year-ago quarter, while the gross margin expanded to 53.7% from 42.1%.
Operating expenses increased modestly to $644,539 from $620,893, while research and development expenses rose to $121,834 from $117,104 in the year-ago quarter.
Total costs and expenses increased 16.4% to $2.39 million from $2.05 million in the year-ago quarter. This comparatively slower expense growth contributed to the substantial improvement in operating profitability.
However, total other income declined to $64,640 from $111,403 in the year-ago quarter. Investment income decreased to $72,556 from $75,165, while marketable securities generated a net loss of $7,916 against a gain of $36,238 a year earlier.
UG's Business Segments Drive Revenue Growth
United-Guardian experienced broad-based sales growth across its principal product categories during the quarter.
Pharmaceutical sales increased 29% year over year, primarily driven by Renacidin, the company's most important pharmaceutical product. Management attributed part of this improvement to expanded formulary coverage achieved earlier in 2026, which supported product demand.
Cosmetic ingredient sales surged 187% from the prior-year quarter, reflecting increased purchases by Ashland Specialty Ingredients, the company's largest marketing partner. This significant increase contributed to the company's overall revenue growth.
Medical lubricant sales increased 20% year over year, supported by higher purchases from a customer in India.
The simultaneous improvement across these businesses indicates that quarterly revenue growth was not limited to a single product category, although the reported figures do not quantify individual segment contributions to consolidated sales.
UG's 9-Month Financial Performance
For the nine months ended Sept. 30, 2026, United-Guardian reported net sales of $9.48 million, representing a 25% increase from $7.58 million in the comparable 2025 period.
Net income increased 70% to $2.48 million from $1.46 million, while earnings rose to 54 cents from 32 cents.
Operating income increased to $2.51 million from $1.52 million, reinforcing the improvement in profitability.
The nine-month results also included $339,493 in settlement income and an $8,310 gain on asset sales. These items were not recorded in the third quarter, distinguishing their contribution to year-to-date earnings from the quarter's operating improvement.
UG's Management Commentary
President Donna Vigilante expressed satisfaction with the company's third-quarter performance, highlighting sales increases across pharmaceuticals, personal care and medical lubricants.
Management indicated that growth initiatives had delivered encouraging results during the first nine months of 2026 and emphasized plans to sustain this momentum.
In pharmaceuticals, United-Guardian is evaluating marketing initiatives intended to increase awareness of Renacidin among healthcare professionals. These efforts could support future sales, although their financial contribution remains uncertain.
Within personal care, the company has a product in late-stage development, with a launch planned for early 2027. This initiative could broaden its product portfolio and provide an additional growth opportunity.
View the Zacks #1 Rank List
Image: Bigstock
UG Stock Gains 28% After Q3 Earnings Surge Y/Y on Sales Growth
Shares of United-Guardian, Inc. (UG - Free Report) have risen 28% since reporting results for the third quarter of 2026, outperforming the S&P 500 index’s 1.9% return. Over the past month, the stock has gained 25.2%, contrasting with the S&P 500’s 4.5% decline.
United-Guardian reported third-quarter 2026 net sales of $3.49 million, up 54% from $2.26 million in the year-ago quarter. Net income surged 247% to $930,912 from $268,441 in the year-ago quarter. Earnings per share increased to 20 cents from 6 cents in the prior-year period. The substantial improvement in profitability reflected higher sales across the company’s pharmaceuticals, personal care ingredients and medical lubricants businesses, alongside relatively modest growth in total costs and expenses.
United-Guardian, Inc. Price, Consensus and EPS Surprise
United-Guardian, Inc. price-consensus-eps-surprise-chart | United-Guardian, Inc. Quote
UG's Operating Income & Expense Trends
Income from operations increased significantly to $1.11 million from $215,072 in the prior-year quarter, reflecting improved operating efficiency and stronger sales performance.
Cost of sales increased 23.5% year over year to $1.62 million from $1.31 million, substantially below the 54% revenue growth rate. Consequently, gross profit increased to $1.88 million from $953,069 in the year-ago quarter, while the gross margin expanded to 53.7% from 42.1%.
Operating expenses increased modestly to $644,539 from $620,893, while research and development expenses rose to $121,834 from $117,104 in the year-ago quarter.
Total costs and expenses increased 16.4% to $2.39 million from $2.05 million in the year-ago quarter. This comparatively slower expense growth contributed to the substantial improvement in operating profitability.
However, total other income declined to $64,640 from $111,403 in the year-ago quarter. Investment income decreased to $72,556 from $75,165, while marketable securities generated a net loss of $7,916 against a gain of $36,238 a year earlier.
UG's Business Segments Drive Revenue Growth
United-Guardian experienced broad-based sales growth across its principal product categories during the quarter.
Pharmaceutical sales increased 29% year over year, primarily driven by Renacidin, the company's most important pharmaceutical product. Management attributed part of this improvement to expanded formulary coverage achieved earlier in 2026, which supported product demand.
Cosmetic ingredient sales surged 187% from the prior-year quarter, reflecting increased purchases by Ashland Specialty Ingredients, the company's largest marketing partner. This significant increase contributed to the company's overall revenue growth.
Medical lubricant sales increased 20% year over year, supported by higher purchases from a customer in India.
The simultaneous improvement across these businesses indicates that quarterly revenue growth was not limited to a single product category, although the reported figures do not quantify individual segment contributions to consolidated sales.
UG's 9-Month Financial Performance
For the nine months ended Sept. 30, 2026, United-Guardian reported net sales of $9.48 million, representing a 25% increase from $7.58 million in the comparable 2025 period.
Net income increased 70% to $2.48 million from $1.46 million, while earnings rose to 54 cents from 32 cents.
Operating income increased to $2.51 million from $1.52 million, reinforcing the improvement in profitability.
The nine-month results also included $339,493 in settlement income and an $8,310 gain on asset sales. These items were not recorded in the third quarter, distinguishing their contribution to year-to-date earnings from the quarter's operating improvement.
UG's Management Commentary
President Donna Vigilante expressed satisfaction with the company's third-quarter performance, highlighting sales increases across pharmaceuticals, personal care and medical lubricants.
Management indicated that growth initiatives had delivered encouraging results during the first nine months of 2026 and emphasized plans to sustain this momentum.
In pharmaceuticals, United-Guardian is evaluating marketing initiatives intended to increase awareness of Renacidin among healthcare professionals. These efforts could support future sales, although their financial contribution remains uncertain.
Within personal care, the company has a product in late-stage development, with a launch planned for early 2027. This initiative could broaden its product portfolio and provide an additional growth opportunity.